Additionally, the combination of IL-1R2 neutralizing antibodies with anti-PD-1 therapy has demonstrated potent antitumor efficacy in triple-negative breast cancer (TNBC) patients51. The gene discussed is PDCD1; the disease is triple-negative breast carcinoma.